GLG News by Users of Triage BNP Test (US)

Joseph SchappertMedical Director PROVIDENCE HEALTH CARE

Surgical Pathology 'Goldrush'

February 13, 2009

Analysis of:Dako announces a collaboration with OSI Pharmaceuticals, Inc. on Companion Diagnostics | www.tmcnet.com

The ability of pharma and biotech to leverage the rapid expansion in our knowledge base on cell surface, nuclear and cytoplasmic signaling and messaging systems has and will continue to produce novel targeted molecules. To identify which patients will respond and potential surrogate markers for the assessment of a molecule's success will require reagents that are applied to histologic sections. These capabilities, combined with imaging and data reduction of the stained sections, should be anticipated to provide a very lucrative market for companies in this diagnostic arena and to facilitate the timely introduction of effective novel markers.

Joseph SchappertMedical Director PROVIDENCE HEALTH CARE

Novel molecules and diagnostic tests

February 19, 2008

Analysis of:Kidney Cancer Drug Linked to Higher Rate of Heart Problems | www.washingtonpost.com

Diagnostic tools are availible to identify these adverse effects at an early stage in their clinical development. These tools should mitigate the seriousness of these adverse events.

Joseph SchappertMedical Director PROVIDENCE HEALTH CARE

Microrganisms elude our control

March 5, 2007

Analysis of:Proof Nailed Down that Antibiotics Use Leads to Resistance | www.medpagetoday.com

Our experience with antibiotics has consistently shown that resistance occurs within 3-5 years of their widespread utilization. Our more recent experience with antiviral agents has been similar. Without diminishing the important role that antimicrobials have played in our recent history, it has also underscored their limitations. While this is of concern, there is also considerable concern in the international microbiology community regarding mutations within microorganisms that would allow them to 'jump species' and infect humans, or would enhance the virulence of existing pathogens. This fear is enhanced by the indiscriminate utilization of antimicrobial agents associated with ‘modern’ agricultural practices worldwide, which are changing the microbial ecology and potentially selecting out new pathogens to humans and/or to our food supply.

 

Joseph SchappertMedical Director PROVIDENCE HEALTH CARE

The future of clinical laboratory diagnostics

March 5, 2007

Analysis of:GE to acquire Abbott's invitro and point of care diagnostics businesses | egems.gehealthcare.com

The purchase of Abbott Diagnostics (ADD) by General Electric follows the purchase of Bayer Diagnostics and DPC by Siemens. It can be anticipated that GE will purchase a second diagnostics company. Since this is part of a restructuring of the diagnostics industry away from pharmaceutical companies to electronics companies, it should also be anticipated that Philips and possibly IBM would enter this arena in the very near future

Page : 11 to 4 of 4